|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM214 |
Gene summary for TMEM214 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM214 | Gene ID | 54867 |
| Gene name | transmembrane protein 214 | |
| Gene Alias | TMEM214 | |
| Cytomap | 2p23.3 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | Q6NUQ4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54867 | TMEM214 | P24T-E | Human | Esophagus | ESCC | 1.10e-18 | 3.83e-01 | 0.1287 |
| 54867 | TMEM214 | P26T-E | Human | Esophagus | ESCC | 1.03e-18 | 2.99e-01 | 0.1276 |
| 54867 | TMEM214 | P27T-E | Human | Esophagus | ESCC | 1.51e-19 | 2.83e-01 | 0.1055 |
| 54867 | TMEM214 | P28T-E | Human | Esophagus | ESCC | 7.24e-16 | 2.22e-01 | 0.1149 |
| 54867 | TMEM214 | P30T-E | Human | Esophagus | ESCC | 9.46e-12 | 4.58e-01 | 0.137 |
| 54867 | TMEM214 | P31T-E | Human | Esophagus | ESCC | 1.48e-19 | 3.18e-01 | 0.1251 |
| 54867 | TMEM214 | P32T-E | Human | Esophagus | ESCC | 1.96e-25 | 4.88e-01 | 0.1666 |
| 54867 | TMEM214 | P36T-E | Human | Esophagus | ESCC | 7.31e-19 | 4.87e-01 | 0.1187 |
| 54867 | TMEM214 | P37T-E | Human | Esophagus | ESCC | 6.61e-18 | 3.61e-01 | 0.1371 |
| 54867 | TMEM214 | P39T-E | Human | Esophagus | ESCC | 3.46e-11 | 1.24e-01 | 0.0894 |
| 54867 | TMEM214 | P40T-E | Human | Esophagus | ESCC | 9.85e-07 | 2.16e-01 | 0.109 |
| 54867 | TMEM214 | P42T-E | Human | Esophagus | ESCC | 3.57e-14 | 3.07e-01 | 0.1175 |
| 54867 | TMEM214 | P44T-E | Human | Esophagus | ESCC | 1.06e-05 | 2.34e-01 | 0.1096 |
| 54867 | TMEM214 | P47T-E | Human | Esophagus | ESCC | 5.76e-17 | 2.42e-01 | 0.1067 |
| 54867 | TMEM214 | P48T-E | Human | Esophagus | ESCC | 3.70e-09 | 1.14e-01 | 0.0959 |
| 54867 | TMEM214 | P49T-E | Human | Esophagus | ESCC | 1.38e-06 | 5.22e-01 | 0.1768 |
| 54867 | TMEM214 | P52T-E | Human | Esophagus | ESCC | 1.69e-22 | 4.00e-01 | 0.1555 |
| 54867 | TMEM214 | P54T-E | Human | Esophagus | ESCC | 2.10e-19 | 2.93e-01 | 0.0975 |
| 54867 | TMEM214 | P56T-E | Human | Esophagus | ESCC | 4.47e-10 | 5.01e-01 | 0.1613 |
| 54867 | TMEM214 | P57T-E | Human | Esophagus | ESCC | 1.04e-15 | 3.53e-01 | 0.0926 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM214 | SNV | Missense_Mutation | novel | c.713T>C | p.Leu238Pro | p.L238P | Q6NUQ4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| TMEM214 | SNV | Missense_Mutation | novel | c.539N>A | p.Gly180Glu | p.G180E | Q6NUQ4 | protein_coding | deleterious(0.03) | benign(0.274) | TCGA-A2-A259-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| TMEM214 | SNV | Missense_Mutation | novel | c.520N>T | p.Val174Leu | p.V174L | Q6NUQ4 | protein_coding | tolerated(0.29) | benign(0.084) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| TMEM214 | SNV | Missense_Mutation | novel | c.739N>G | p.Ser247Ala | p.S247A | Q6NUQ4 | protein_coding | tolerated(0.06) | possibly_damaging(0.825) | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM214 | SNV | Missense_Mutation | c.1588N>A | p.Ala530Thr | p.A530T | Q6NUQ4 | protein_coding | tolerated(0.35) | benign(0.006) | TCGA-BH-A1FG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM214 | SNV | Missense_Mutation | c.1064G>C | p.Gly355Ala | p.G355A | Q6NUQ4 | protein_coding | deleterious(0.05) | benign(0.271) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM214 | SNV | Missense_Mutation | rs368363508 | c.548N>A | p.Arg183Gln | p.R183Q | Q6NUQ4 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-D8-A27L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin+cuclophosphamide | SD |
| TMEM214 | insertion | In_Frame_Ins | novel | c.715_716insCAGTGGGAGAAATGACCGCCACACACTCAACACTCACCA | p.Gly239delinsAlaValGlyGluMetThrAlaThrHisSerThrLeuThrSer | p.G239delinsAVGEMTATHSTLTS | Q6NUQ4 | protein_coding | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TMEM214 | insertion | Frame_Shift_Ins | novel | c.1822_1823insCTCCCAGGGAGGGGAGAGGAGAGGCAGAAGAG | p.Gln608ProfsTer17 | p.Q608Pfs*17 | Q6NUQ4 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TMEM214 | insertion | Frame_Shift_Ins | novel | c.337_338insCC | p.Glu113AlafsTer4 | p.E113Afs*4 | Q6NUQ4 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |